Efgartigimod works through an elegant molecular trick. It is a human immunoglobulin G1 (IgG) antibody Fc fragment, engineered to bind with unusually high affinity to the neonatal Fc receptor (FcRn), the cellular recycling machinery that normally protects IgG antibodies from degradation and gives them their characteristically long half-life in the bloodstream. By occupying FcRn, efgartigimod interrupts this recycling loop, so circulating IgG, including the pathogenic autoantibodies that drive diseases like gMG and CIDP, is cleared faster. Importantly, the drug does not suppress antibody production or blunt immune responses to vaccination, and it does not lower albumin levels or raise cholesterol, distinguishing it from broadly immunosuppressive therapies such as glucocorticoids, azathioprine, mycophenolate mofetil, or B cell-depleting agents.

The original subcutaneous formulation contained a fixed 1000-mg dose of efgartigimod at 180 mg/ml in a 5.6-ml volume, supplied in a single-dose vial that a health care provider had to draw up with a separate syringe. The new prefilled syringe packs the same 1000-mg dose into 5.0 ml at a higher concentration of 200 mg/ml, and it was approved in the United States in April 2025 for adults with acetylcholine receptor autoantibody-positive generalized myasthenia gravis and for adults with CIDP. The coformulation with recombinant human hyaluronidase PH20 is what makes such a large subcutaneous volume feasible: the enzyme locally depolymerizes hyaluronan in the subcutaneous space, temporarily dissolving the structural barrier to bulk fluid flow so the drug can disperse and be absorbed more readily.

The first question the researchers tackled was whether the prefilled syringe is pharmacologically interchangeable with the vial-and-syringe presentation. In a Phase 1, open-label, randomized, two-period crossover bioequivalence study (ClinicalTrials.gov identifier NCT05817435), 72 healthy participants each received a single health care provider-administered injection by both routes, serving as their own controls. Serum efgartigimod concentrations were measured with a validated ligand-binding electrochemiluminescence immunoassay with a lower limit of quantification of 200 ng/ml, and the primary endpoints were the maximum observed concentration (Cmax) and the area under the concentration-time curve from zero to infinity (AUC0-inf).

The bioequivalence criterion was met decisively. The 90 percent confidence intervals for the geometric least-squares mean ratios of both Cmax and AUC0-inf fell entirely within the predefined acceptance range of 80.0 to 125.0 percent, the regulatory standard for demonstrating that two formulations deliver equivalent systemic exposure. After injection, efgartigimod concentrations rose to a plateau, with a median time to peak concentration of 48.0 hours for the prefilled syringe versus 72.0 hours for the vial and syringe, and individual values ranging from 12.0 to 119.3 hours. Once the plateau was reached, serum concentrations declined gradually with similar half-lives for both presentations, and other pharmacokinetic parameters were likewise comparable between the two arms.

Safety in the bioequivalence study was reassuring. The drug was well tolerated by both routes, with no fatal or serious adverse events and no discontinuations attributed to adverse events. A single grade 3 or higher event, a blood pressure increase in one participant who received the vial-and-syringe formulation, was judged unrelated to treatment. Injection site reactions occurred in 50.7 percent of participants using the prefilled syringe and 59.7 percent using the vial and syringe, all of grade 1 or 2 severity, and all resolved by the end of the study except one that was resolving. A post hoc analysis showed mean injection durations of roughly 31 seconds in both groups, and no anaphylactic or hypersensitivity reactions were observed.

A second Phase 1 study asked a deceptively simple question: how fast can a large, viscous subcutaneous volume be pushed without causing problems? All 48 randomized healthy participants completed this randomized, open-label crossover trial, in which efgartigimod PH20 SC was delivered over 20, 30, 45, or 60 seconds using an infusion pump with a disposable syringe and a 27-gauge ultra-thin-wall needle. Every participant across every speed group received at least 90 percent of the full injection volume in both dosing periods, and mean fluid leakage or backflow at the injection site was negligible and essentially identical across groups, at 0.0122 ml in the first period and 0.0085 ml in the second. More than 87 percent of participants said one hour after injection that they would be willing to receive the administration again, local pain scores dropped significantly within five minutes across all speed groups, and all adverse events were mild to moderate, with no serious events or discontinuations.

The third component comprised two human factors validation studies, designed according to US Food and Drug Administration guidance for combination products, that tested whether real users could handle the device safely. Fifteen participants with gMG, fifteen with CIDP, and fifteen lay caregivers of family members with these diseases were given the prefilled syringe and its instructions for use, but no training whatsoever. In a simulated home environment, each participant stored the device overnight and then performed an unaided simulated injection into an injection pad, placed over their own clothes for patients or on a manikin for caregivers. The results were striking: all 45 participants successfully refrigerated, prepared, injected, and disposed of the prefilled syringe, delivering the full dose in an average of 30 seconds, with no performance differences between patients and caregivers and no use errors that could cause harm. All 45 also correctly located and identified 28 pieces of critical safety information in the instructions, and every participant said they believed they could give weekly injections with the product if needed.

The authors acknowledge one methodological caveat: the injection speed study used an infusion pump rather than the prefilled syringe device itself, which prevents firm conclusions about the optimal speed of the PFS specifically. However, the formulation tested had the same volume and viscosity as that used in the bioequivalence and human factors studies, which did employ the device, so the data collectively support the feasibility and safety of a rapid, roughly 30-second injection of efgartigimod PH20 SC in general. The researchers also note that the studies were funded by argenx, the drug’s developer, and that several of the authors are company employees, factors readers should weigh when interpreting the uniformly positive findings.

Even with those caveats, the implications for patients are substantial. For chronic conditions like gMG and CIDP, where treatment continues indefinitely, aligning therapy with patient preferences for route of administration has been linked to greater satisfaction, better quality of life, and improved adherence. A prefilled syringe eliminates the steps of vial handling and dose drawing, improves dosing accuracy, and particularly benefits patients with impaired manual dexterity, coordination, or vision, while reducing health care resource utilization and waste. Taken together, the bioequivalence, injection speed, and human factors data indicate that a rapid, high-volume subcutaneous injection of efgartigimod PH20 from a prefilled syringe is safe, feasible, and usable, offering patients and their caregivers a quick, flexible option for receiving treatment either in a clinic or at home, and potentially easing the daily burden of living with IgG-mediated autoimmune disease.

Subject of Research: Pharmacokinetics, injection speed, and usability of a prefilled syringe for subcutaneous efgartigimod PH20 in IgG-mediated autoimmune diseases

Article Title: Investigating the Pharmacokinetics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administered with a Prefilled Syringe

Article References: De Muynck, C., Noukens, J., Allosery, K., Cettour-Rose, C., Pastouret, S., Andre, A. D., & Borgions, F. (2026). Investigating the Pharmacokinetics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administered with a Prefilled Syringe. Advances in Therapy. https://doi.org/10.1007/s12325-026-03733-x

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03733-x

Keywords: efgartigimod, prefilled syringe, bioequivalence, myasthenia gravis, CIDP, neonatal Fc receptor, hyaluronidase PH20, subcutaneous injection, pharmacokinetics, human factors study, autoimmune disease, self-administration

The scale of the problem the researchers confront is enormous. According to the United Nations Office on Drugs and Crime, new psychoactive substances are compounds that threaten public health yet fall outside the 1961 Single Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances. By the end of 2024, the European Union Drugs Agency was monitoring 1,000 such substances in Europe, 47 of them first reported that year. Between 2012 and 2025, the UNODC Early Warning Advisory logged 1,391 new psychoactive substances across 152 countries and territories, while the NPS Discovery program of the Center for Forensic Science Research and Education identified 174 compounds for the first time in the United States between 2018 and 2024, including 20 in 2024 alone. Each new structure demands a rapid toxicological evaluation, and the zebrafish, with its transparent embryos, rapid development, and vertebrate reward circuitry, has become one of the most practical platforms for that task.

The two compounds chosen for this study illustrate the cat-and-mouse dynamics of the synthetic drug market. ADB-INACA is a so-called tail-less precursor, an indazole carboxamide lacking the N-alkyl tail found in potent controlled SCRAs such as ADB-BUTINACA. First flagged by NPS Discovery in 2023, it has since appeared in nine drug-material cases and seven toxicological specimens. CHO-4′Me-5′Br-FUBOXPYRA, by contrast, was engineered with a novel 5-bromo-4-methylpyridin-2(1H)-one core specifically to evade China’s 2021 generic ban on synthetic cannabinoids. First identified in Europe in 2022, it has since surfaced in Germany, Italy, Slovenia, Sweden, Lithuania, Romania, Spain, and, as of 2023, in United States drug material, with a first toxicological detection reported in 2024. Prior receptor studies suggested both compounds carry only limited CB1 activity, making them ideal candidates to test whether structural loopholes translate into genuine physiological risk.

To answer that question, the team, led by Leonardo Costalonga Rodrigues and colleagues at the Universidade Estadual de Campinas in Brazil and the University of Utah, deployed a battery of complementary assays. Acute embryonic toxicity was measured with the fish embryo acute toxicity test standardized by the Organization for Economic Co-operation and Development as guideline 236, in which newly fertilized eggs are exposed to a compound for 96 hours and scored for lethal endpoints: coagulation of the egg, lack of somite formation, failure of the tail bud to detach from the yolk sac, and absence of heartbeat. Concentrations ranged from 0.001 to 10 micromolar, with 16 embryos per concentration, and sublethal observations such as pericardial edema, loss of posture, and heart rate changes were recorded daily under a stereoscopic microscope. At three days post-fertilization, heartbeats of five larvae per group were filmed for 20 seconds and extrapolated to beats per minute, and at four days each larva was touched on the tail with a micropipette tip to test its escape response.

The results from embryonic exposure were strikingly mild. Both SCRAs produced low mortality across the entire tested range, with embryo coagulation the only lethal endpoint observed, and even that appeared in fewer than 19 percent of embryos at any time point. CHO-4′Me-5′Br-FUBOXPYRA, however, did produce sublethal cardiac and postural effects that crossed the study’s 30 percent reporting threshold: pericardial edema at 10 micromolar, loss of posture in 69 percent of larvae at the highest concentration at three days post-fertilization, and a statistically significant reduction in heart rate at 10 micromolar, with a p-value below 0.01. Escape responses were blunted at all concentrations above 0.1 micromolar for this compound. ADB-INACA produced mainly impaired escape responses at select concentrations without significant lethality or cardiac effects. A companion maximum tolerated concentration test in larvae, exposing animals from five to eight days post-fertilization, largely confirmed this picture, with absent escape responses and occasional loss of posture at the highest doses but little else.

The behavioral experiments are where the study breaks genuinely new ground. Social behavior was assessed at 21 days post-fertilization using the Fishbook assay, a scalable, fully automated system first described in 2022. Juvenile zebrafish swim in a three-dimensional-printed rectangular arena divided by transparent windows into a central test compartment, an end compartment holding a live fish as a social stimulus, and an empty end compartment. Forty-four arenas are imaged simultaneously through a telecentric lens system, and software streams frame-by-frame positional coordinates that are converted into a social score between negative one and one, where higher values indicate that a fish spent more time near the social stimulus. Neither compound altered the social score: fish exposed to 10 micromolar ADB-INACA averaged 0.484 versus 0.424 in controls, and fish exposed to 10 micromolar CHO-4′Me-5′Br-FUBOXPYRA averaged 0.658 versus 0.623 in controls. To the researchers’ knowledge, this is the first in vivo evaluation of any SCRA’s impact on social interaction.

The final and arguably most ambitious assay tested whether the new compounds could drive drug-seeking behavior. Building on a paradigm developed by Bossé and Peterson, the team constructed a custom arena with two submersible platforms, an “active” one wired to a Raspberry Pi minicomputer and infrared cameras that trigger a peristaltic pump releasing a drug solution, and an “inactive” one that dispenses nothing. A recirculation system prevented drug diffusion to the inactive corner. Adult zebrafish first learned over five days of food conditioning that crossing the active platform yields a reward, then received five days of drug treatment. Hydrocodone served as the positive control, and it performed as expected: fish consistently sought the opioid, triggering the active platform far more often than the inactive one. Fish exposed to 0.625 micrograms of CHO-4′Me-5′Br-FUBOXPYRA per trigger, however, showed a progressive decline in active-platform crossings indistinguishable from the water-treated controls, indicating the compound lacked reinforcing effects under these conditions. ADB-INACA was not carried into self-administration testing because the earlier toxicity assays had revealed no significant effects.

The authors connect their findings to the wider pharmacological literature on these structural families. Earlier work on tail-less indazole precursors found minimal CB1 receptor activity for ADB-INACA, with concentration-response curves that failed to reach a clear plateau and potency estimates that could not be determined, while brominated analogs showed only partial receptor activation even at 100 micromolar. For CHO-4′Me-5′Br-FUBOXPYRA, a 2025 investigation of its metabolism identified four hydroxylated metabolites and a limited activation potential at both CB1 and CB2. The new zebrafish data align neatly with that weak receptor profile: limited cannabinoid-like behavioral effects, normal social behavior, no drug-seeking, and only modest cardiotoxicity for the brominated pyridone compound in the form of pericardial edema and reduced heart rate at the highest concentration tested. The study does have limitations the authors themselves acknowledge: only two compounds were evaluated, exposures were acute rather than chronic, and no molecular or neurochemical endpoints were measured to confirm what the receptors were doing during the behavioral tests.

Even so, the methodological takeaway may prove more consequential than the individual toxicological verdicts. By combining OECD-standard embryo testing, larval maximum tolerated concentration assays, the automated Fishbook social paradigm, and an operant self-administration assay within a single vertebrate model, the study demonstrates an end-to-end pipeline capable of profiling a novel psychoactive substance from developmental toxicity to abuse liability in a matter of weeks. The authors describe these assays as feasible, reproducible, and translationally relevant, and argue that they can be extended to a much larger number of emerging compounds, offering a rapid toxicological surveillance bridge between preclinical toxicology and public health needs. As forensic chemists continue to identify new SCRAs faster than regulators can schedule them, the humble zebrafish may become one of the fastest ways to learn whether the next designer cannabinoid is a genuine threat or, as appears to be the case for ADB-INACA and CHO-4′Me-5′Br-FUBOXPYRA at the concentrations tested, a structural dodge with surprisingly little punch.

Subject of Research: Toxicity and behavioral effects of the synthetic cannabinoid receptor agonists ADB-INACA and CHO-4′Me-5′Br-FUBOXPYRA in zebrafish models

Article Title: Evaluation of synthetic cannabinoid receptor agonists toxicity in zebrafish (Danio rerio) through self-administration and Fishbook assays

Article References: Rodrigues, L. C., Muhsen, M., Aliabadi, S. R., Zhang, T., Maurer-Morelli, C. V., Peterson, R. T., & Costa, J. L. (2026). Evaluation of synthetic cannabinoid receptor agonists toxicity in zebrafish (Danio rerio) through self-administration and Fishbook assays. Discover Toxicology, 3(1), Article 4. https://doi.org/10.1007/s44339-026-00049-x

Image Credits: AI Generated

DOI: 10.1007/s44339-026-00049-x

Keywords: synthetic cannabinoids, new psychoactive substances, zebrafish, toxicology, ADB-INACA, CHO-4′Me-5′Br-FUBOXPYRA, Fishbook assay, self-administration, drug-seeking behavior, CB1 receptor, embryotoxicity, social behavior